Dr. Michael Macklin is a faculty member of the Section of Rheumatology at the University of Chicago, an expert in the care of patients with systemic sclerosis (scleroderma) and interstitial lung diseases (ILD). Dr. Michael Macklin is the director of the multidisciplinary Scleroderma Program at the University of Chicago, encompassing specialists in Pulmonary, Cardiology, Gastroenterology, Plastic Surgery, and Dermatology, who provide comprehensive care to individuals carrying the diagnosis of systemic sclerosis (scleroderma).He has worked on projects devoted to improving the diagnosis and treatment of individuals of systemic sclerosis. His clinical research has focused on clinical trials for patients with systemic sclerosis, including cell therapy such as CAR-T cells.
Dr. Michael Macklin is also a member of the multidisciplinary interstitial lung disease (ILD) group at the University of Chicago and hosts a combined rheumatology-pulmonary clinic dedicated to patients with ILD due to autoimmune diseases. The ILD Program at the University of Chicago has been internationally recognized for its innovative and collaborative clinical research in ILD and also provides clinical trials for these diseases.
Dr. Michael Macklin also has an interest in IgG4 related disease and is a member of the multidisciplinary IgG4 Clinical Consortium at the University of Chicago, encompassing specialists from Gastroenterology, Pathology, Nephrology, Ophthalmology and Neurology.
Dr. Michael Macklin also is very interested in medical education and works with learners at all stages in their medical training.
Therapeutic Choices in Systemic Sclerosis-Associated Interstitial Lung Disease, a Survey of 2 International Research Groups.
Therapeutic Choices in Systemic Sclerosis-Associated Interstitial Lung Disease, a Survey of 2 International Research Groups. J Clin Rheumatol. 2025 Oct 01; 31(7):284-287.
PMID: 40489954
Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine.
Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine. JCI Insight. 2024 Apr 30; 9(11).
PMID: 38687615
Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation.
Linking Adiposity to Interstitial Lung Disease: The Role of the Dysfunctional Adipocyte and Inflammation. Cells. 2023 09 05; 12(18).
PMID: 37759429
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics.
Checkpoint Inhibitor-Associated Scleroderma and Scleroderma Mimics. Pharmaceuticals (Basel). 2023 Feb 08; 16(2).
PMID: 37259404
The prevalence and density of asymptomatic Plasmodium falciparum infections among children and adults in three communities of western Kenya.
The prevalence and density of asymptomatic Plasmodium falciparum infections among children and adults in three communities of western Kenya. Malar J. 2021 Sep 17; 20(1):371.
PMID: 34535134
Synergistic malaria vaccine combinations identified by systematic antigen screening.
Synergistic malaria vaccine combinations identified by systematic antigen screening. Proc Natl Acad Sci U S A. 2017 11 07; 114(45):12045-12050.
PMID: 29078270